Can Weight‑Loss Drugs Become a New Weapon Against Cancer? The Hot Question During the World Cup

## Introduction

## How GLP‑1 Drugs Work and Their Potential Anti‑Cancer Effects Modern weight‑loss drugs belong to the GLP‑1 class, mimicking an intestinal hormone that enhances satiety and improves blood‑sugar regulation. Beyond weight loss, pre‑clinical research suggests GLP‑1 may influence cellular pathways tied to tumor growth, such as reducing inflammation and improving insulin sensitivity. In a study involving over 161,000 participants without diabetes or prior cancer, researchers observed a marked reduction in breast, colon, and pancreatic cancer rates among drug users compared to a control group receiving diet and exercise counseling only. These findings imply that the benefit may extend beyond mere weight reduction to altering the internal biological environment in ways that suppress tumor formation.

## Gender and Racial Differences in Cancer Risk Reduction Data analysis revealed notable disparities in how GLP‑1 drugs affect cancer risk across genders and ethnicities. Men experienced about a 70% risk drop, considerably higher than women. Regarding race, the study reported a clear risk reduction among White participants, while Black participants did not see the same magnitude of benefit. Potential explanations include genetic variations, lifestyle differences, and unequal access to quality healthcare. These disparities push researchers to design further trials that may adjust dosages or drug formulations to better serve each demographic group.